Differential expression of CD57 in antigen-reactive CD4+ T cells between active and latent tuberculosis infection

Clinical Immunology

Volumn 159, Issue 1, 2015, Pages 37-46

  Lee, Ji Yeon ^a   Jeong, Ina ^a   Joh, Joon Sung ^a   Jung, Young Won ^b   Sim, Soo Yeon ^a   Choi, Boram ^a   Jee, Hyeon Gun ^a   Lim, Dong Gyun ^a  

^a National Medical Center   (South Korea)

^b Jung gu Community Mental Health Center   (South Korea)

Author keywords

Biomarker; CD4+ T cell; CD57; Tuberculosis

Indexed keywords

CD57 ANTIGEN; CULTURE FILTRATE PROTEIN 10; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MYCOBACTERIUM ANTIGEN; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIVISION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; LYMPHOCYTE DIFFERENTIATION; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE SUBPOPULATION; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD57; BIOLOGICAL MARKERS; BIOMARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LATENT TUBERCULOSIS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929470520     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.04.011     Document Type: Article

References (48)

1. Vynnycky E., Fine P.E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 2000, 152:247-263.
2. Andrews J.R., Noubary F., Walensky R.P., Cerda R., Losina E., Horsburgh C.R. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 2012, 54:784-791.
3. Horsburgh C.R., Rubin E.J. Latent tuberculosis infection in the United States. N. Engl. J. Med. 2011, 364:1441-1448.
4. Rangaka M.X., Wilkinson K.A., Glynn J.R., Ling D., Menzies D., Mwansa-Kambafwile J., Fielding K., Wilkinson R.J., Pai M. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12:45-55.
5. Sutherland J.S., Hill P.C., Adetifa I.M., de Jong B.C., Donkor S., Joosten S.A., Opmeer L., Haks M.C., Ottenhoff T.H., Adegbola R.A., Ota M.O. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One 2011, 6:e25230.
6. Hussain R., Talat N., Ansari A., Shahid F., Hasan Z., Dawood G. Endogenously activated interleukin-4 differentiates disease progressors and non-progressors in tuberculosis susceptible families: a 2-year biomarkers follow-up study. J. Clin. Immunol. 2011, 31:913-923.
7. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., Wilkinson K.A., Banchereau R., Skinner J., Wilkinson R.J., Quinn C., Blankenship D., Dhawan R., Cush J.J., Mejias A., Ramilo O., Kon O.M., Pascual V., Banchereau J., Chaussabel D., O'Garra A. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
8. Kaufmann S.H. Tuberculosis vaccines: time to think about the next generation. Semin. Immunol. 2013, 25:172-181.
9. Havlir D.V., Barnes P.F. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 1999, 340:367-373.
10. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamso R., Levin M. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 1996, 335:1941-1949.
11. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with inflixmab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345:1098-1104.
12. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007, 8:369-377.
13. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P.R. The immune response in tuberculosis. Annu. Rev. Immunol. 2013, 31:475-527.
14. + regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin. Immunol. 2007, 123:50-59.
15. Scott-Browne J.P., Shafiani S., Tucker-Heard G., Ishida-Tsubota K., Fontenot J.D., Rudensky A.Y., Bevan M.J., Urdahl K.B. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 2007, 204:2159-2169.
16. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188:2205-2213.
17. Brenchley J.M., Karandikar N.J., Betts M.R., Ambrozak D.R., Hill B.J., Crotty L.E., Casazza J.P., Kuruppu J., Migueles S.A., Connors M., Roederer M., Douek D., Koup R.A. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003, 101:2711-2720.
18. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 2010, 28:445-489.
19. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
20. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
21. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., Gyenes G., Vali B., Hyrcza M.D., Yue F.Y., Kovacs C., Sassi A., Loutfy M., Halpenny R., Persad D., Spotts G., Hecht F.M., Chun T.W., McCune J.M., Kaul R., Rini J.M., Nixon D.F., Ostrowski M.A. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205:2763-2779.
22. Day C.L., Abrahams D.A., Lerumo L., van Rensburg E.J., Stone L., O'rie T., Pienaar B., de Kock M., Kaplan G., Mahomed H., Dheda K., Hanekom W.A. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 2011, 187:2222-2232.
23. Rueda C.M., Marin N.D., Garcia L.F., Rojas M. Characterization of CD4 and CD8 T cells producing IFN-γ in human latent and active tuberculosis. Tuberculosis 2010, 90:346-353.
24. Flynn J.L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 2001, 19:93-129.
25. Sester U., Fousse M., Dirks J., Mack U., Prasse A., Singh M., Lalvani A., Sester M. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active status. PLoS One 2011, 6:e17813.
26. Pollock K.M., Whitworth H.S., Montamat-Sicotte D.J., Grass L., Cooke G.S., Kapembwa M.S., Kon O.M., Sampson R.D., Taylor G.P., Lalvani A. T-cell immunophenotyping distinguishes active from latent tuberculosis. J. Infect. Dis. 2013, 208:952-968.
27. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional Th1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
28. Sutherland J.S., Adetifa I.M., Hill P.C., Adegbola R.A., Ota M.O.C. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 2009, 39:723-729.
29. + T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 2010, 40:2211-2220.
30. Casey R., Blumenkrantz D., Millington K., Montamat-Sicotte D., Kon O.M., Wickremasinghe M., Bremang S., Magtoto M., Sridhar S., Connell D., Lalvani A. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS One 2010, 5:e15619.
31. Semple P.L., Binder A.B., Davids M., Maredza A., van Zyl-Smit R.N., Dheda K. Regulatory T cells attenuate mycobacterial stasis in alveolar and blood-derived macrophages from patients with tuberculosis. Am. J. Respir. Crit. Care Med. 2013, 187:1249-1258.
32. Cowan J., Pandey S., Filion L.G., Angel J.B., Kumar A., Cameron D.W. Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin. Exp. Immunol. 2012, 167:317-329.
33. Jurado J.O., Pasquinelli V., Alvarez I.B., Pena D., Rovetta A.I., Tateosian N.L., Romeo H.E., Musella R.M., Palmero D., Chuluyan H.E., Garcia V.E. IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J. Leukoc. Biol. 2012, 91:991-1002.
34. + T cells in active disease. Eur. J. Immunol. 2013, 43:939-948.
35. Hughes A.J., Hutchinson P., Gooding T., Freezer N.J., Holdsworth S.R., Johnson P.D.R. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin. Exp. Immunol. 2005, 142:132-139.
36. + T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis. 2000, 181:1194-1197.
37. + T cells in the disease activity of rheumatoid arthritis. Arthritis Rheum. 2002, 46:379-384.
38. + T cells to immune senescence. J. Immunol. 2009, 183:4103-4108.
39. + T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood 1992, 79:1746-1753.
40. + T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 2004, 111:100-106.
41. Guglielmetti L., Cazzadori A., Conti M., Boccafoglio F., Vella A., Ortolani R., Concia E. Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay. Int. J. Tuberc. Lung Dis. 2013, 17:825-828.
42. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
43. Singh A., Mohan A., Dey A.B., Mitra D.K. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J. Infect. Dis. 2013, 208:603-615.
44. Henao-Tamayo M., Irwin S.M., Shang S., Ordway D., Orme I.M. T lymphocyte surface expression markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis 2011, 91:308-313.
45. Reiley W.W., Shafiani S., Wittmer S.T., Tucker-Heard G., Moon J.J., Jenkins M.K., Urdahl K.B., Winslow G.M., Woodland D.L. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19408-19413.
46. + T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One 2012, 7:e36046.
47. + T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog. 2012, 8:e1002984.
48. Jurado J.O., Alvarez I.B., Pasquinelli V., Martinez G.J., Quiroga M.F., Abbate E., Musella R.M., Chuluyan H.E., Garcia V.E. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 2008, 181:116-125.